Maternal-perinatal outcomes in pregnant women with COVID-19 in a level III hospital in Peru

The present study aimed to describe the perinatal outcomes of newborns of mothers with 2019 coronavirus infection identified before delivery in a level III hospital in Peru. Sociodemographic variables, obstetric complications, and neonatal morbidities were evaluated in the births that occurred betwe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Revista peruana de medicina experimental y salud pública 2021-03, Vol.38 (1), p.58-63
Hauptverfasser: Carmen Dávila-Aliaga, Rosmary Hinojoza-Pérez, Marcos Espinola-Sánchez, Elsa Torres-Marcos, Enrique Guevara-Ríos, Ylia Espinoza-Vivas, Elina Mendoza-Ibañez, Claudia Saldaña-Díaz
Format: Artikel
Sprache:spa
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The present study aimed to describe the perinatal outcomes of newborns of mothers with 2019 coronavirus infection identified before delivery in a level III hospital in Peru. Sociodemographic variables, obstetric complications, and neonatal morbidities were evaluated in the births that occurred between April 1 and June 30, 2020, at the National Maternal Perinatal Institute of Peru. 43 newborns were registered: 93% came from asymptomatic mothers, the most frequent obstetric complications were premature rupture of membranes (18.6%) and pre-eclampsia (11.6%), 65.1% of the births were vaginally, only one of the newborns had a positive result to RT-PCR for COVID-19, the comorbidities of the newborns were prematurity (11.3%) and low birth weight (9.3%); four were admitted to intermediate care and two to intensive care. It is concluded that 2.4% of newborns born to mothers with COVID-19 presented positive molecular test of RT-PCR, 14% of newborns presented morbidity as prematurity, low birth weight, sepsis and pneumonia that required ventilation. Neonatal morbidity was found in newborns whose RT-PCR test was negative for COVID-19.
ISSN:1726-4634
1726-4642
DOI:10.17843/rpmesp.2021.381.6358